Company | Profile
Syqe Medical's pocket-sized medical marijuana inhaler was approved in 2015 by Israel’s Ministry of Health as one of the only such devices that is able to deliver controlled doses of THC to patients. (It uses a proprietary system of preloaded cartridges and metered-dose delivery.) In clinical settings, it is meant to be used in pain-relief centers, cancer-treatment departments, and ICUs. So far, the device has been used only at Israel's Rambam Hospital, but 2017 is shaping up to be a big year for the company. Syqe recently signed a distribution agreement with the world’s leading producer of generic drugs, Teva Pharmaceutical Industries, and Philip Morris International invested $20 million in Syqe—and licensed its technology, one of the first times that Big Tobacco is collaborating with a cannabis-related company. In 2017, Syqe will make the inhaler available for home use. (The company expects the Ministry of Health to grant approval soon.) It plans to use the inhaler for delivering other herbs medicinally, too.